Search for: "Amgen, Inc. v. Hoechst Marion Roussel, Inc."
Results 1 - 20
of 41
Sort by Relevance
|
Sort by Date
30 Apr 2024, 7:30 am
Amgen Inc. v. [read post]
8 Mar 2023, 2:51 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1330 (Fed. [read post]
17 Mar 2022, 2:32 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. [read post]
26 Aug 2021, 1:05 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1330 (Fed. [read post]
9 Jun 2018, 7:01 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313,1354 (Fed. [read post]
26 Jul 2017, 3:49 am
As explained in paragraph 42 of this judgment, in paragraph 37 of Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9, Lord Hoffmann explained that the doctrine of equivalents had been developed in the United States. [read post]
26 Jul 2017, 3:49 am
As explained in paragraph 42 of this judgment, in paragraph 37 of Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9, Lord Hoffmann explained that the doctrine of equivalents had been developed in the United States. [read post]
6 Apr 2017, 1:35 pm
”); MortonInt’l, Inc. v. [read post]
26 Nov 2015, 8:12 am
Per the precedent set in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46 (and other cases since), the question is "...what the person skilled in the art would have understood the Patentee to be using the language of the claim to mean". [read post]
19 Oct 2015, 1:39 pm
Hoechst Marion Roussel, Inc., 314F.3d 1313, 1354 (Fed. [read post]
30 Jul 2015, 9:50 am
That is what today's decision addresses.Appeal to the Supreme CourtThe Court of Appeal has refused leave for Smith & Nephew to appeal to the Supreme Court, because it considered that there is no significant point of general public importance at stake, since it has done no more than apply the established principles of claim construction from Kirin Amgen (Kirin Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005]… [read post]
12 Dec 2014, 10:29 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1355-56 (Fed. [read post]
2 Feb 2014, 9:40 am
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1342 (Fed. [read post]
5 Aug 2012, 9:04 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1354 (Fed. [read post]
27 Jul 2012, 11:44 am
Hoechst Marion Roussel, Inc. [read post]
18 Jul 2012, 4:52 am
" "The second is that it is necessary to distinguish between claims that are difficult to construe or that have a "fuzzy boundary" (in the words of Lord Hoffmann in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005] RPC 9 at [126]) on the one hand from claims that are truly ambiguous on the other. [read post]
24 May 2012, 5:01 pm
This is an appeal against the revocation of the patent under consideration by the Opposition Division (OD).Claim 1 of the main request before the Board was identical to claim 1 as granted and read:1. [read post]
28 Jul 2011, 3:00 am
Distinct issues of construction arose in respect of claims 1 and 3 of the patent:Claim 1:A wound dressing comprising a blend of discrete modified cellulose gel forming fibres with at least one other type of discrete gel forming fibres.Claim 3:A wound dressing as claimed in any preceding claim wherein the dressing comprises a wound contacting surface consisting of a blend of discrete modified cellulose fibres with at least one other type of discrete gel forming fibres.Setting out the law, the Judge… [read post]
5 Jul 2011, 1:44 pm
Sighted this morning, breaking the surface just off the Strand, the judgment of Mr Justice Arnold in MedImmune v Novartis [2011] EWHC 1669 (Pat) certainly fits the legend.In characteristic style, the judgment is as comprehensive as one would wish. [read post]
2 May 2011, 3:14 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1339 (Fed. [read post]
